GlassScriptPhysician profile
Joseph T Vitale
NPI 1780965905
$6,314.32
in general payments reported to CMS, 2019-2025
50 companies · $816 in 2025
The $816 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $564 · 2021: $803 · 2022: $836 · 2023: $1,072 · 2024: $1,311 · 2025: $816.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,191 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,190.77 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $981.39 | 2021-2025 | Vraylar, Qulipta, Linzess |
| Glaxosmithkline, LLC. | $691.41 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $539.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $486.65 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $477.32 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Pfizer INC. | $327.19 | 2019-2025 | |
| Allergan, INC. | $311.42 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $277.83 | 2021-2023 | |
| Amarin Pharma, INC. | $204.03 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $173.84 | 2022 | |
| Ironwood Pharmaceuticals, INC | $151.98 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $132.90 | 2023 | Ingrezza |
| Genzyme Corporation | $114.55 | 2024 | |
| Exact Sciences Corporation | $95.66 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $88.43 | 2019-2023 | Veozah |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Vitale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.